Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03906669
Other study ID # ACTRN1261000928213
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 20, 2018
Est. completion date April 2024

Study information

Verified date November 2023
Source St Vincent's Hospital
Contact Robert Kent
Phone +61293555611
Email SVHS.CancerResearch@svha.org.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase II randomised, open label study of pre-operative endocrine therapy with & without prometrium in postmenopausal women with early stage breast hormone receptor positive (HR+) human epidermal receptor 2 negative (HER2-) breast cancer.


Description:

There is bidirectional interplay between the progesterone receptor (PR) and oestrogen receptor (ER) in human breast cancers. There is evidence for a reprogramming of ER chromatin binding sites with 470 genes differentially regulated by dual treatment with estrogen plus progestogen compared to estrogen alone in breast cancer cell lines. Functionally, there was an additive anti-cancer effect with the addition of natural progesterone to endocrine therapy in preclinical breast cancer models. This is a phase II multi-site, randomised, open-label, three-arm, study in 200 postmenopausal women with early-stage ER+, PR+, HER2-negative breast cancer. Eligible patients will be randomised (1:1:1) to receive 14 days of intervention with either letrozole 2.5mg PO daily (arm 1), letrozole 2.5mg + prometrium 300mg PO daily (arm 2) or tamoxifen 20mg + prometrium 300mg PO daily (arm 3), between diagnosis of breast cancer and definitive surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date April 2024
Est. primary completion date April 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically confirmed ER+ and PR+ breast cancer (defined as =10% positive staining cells) 2. Histologically confirmed HER2-negative breast cancer (defined as IHC 0-1 and/or FISH/CISH <2.2) 3. Tumour size =1 cm as measured by ultrasound and/or mammogram 4. Ability to understand all patient information and informed-consent documents, written informed consent to participate in the trial, and to avail tissue and blood samples for research 5. Aged 18 years or older Exclusion Criteria: 1. Women currently on hormone therapies, including hormone replacement therapy and oral contraceptive pill 2. Locally advanced/inoperable and inflammatory breast cancer 3. Planned for a mastectomy (due to increased risk of venous thromboembolism) 4. Clinical evidence of metastatic disease 5. Patients treated with other preoperative systemic therapies 6. Nut allergy (prometrium contains peanut oil) 7. Prior history of uterine cancer, deep vein thrombosis, pulmonary embolism or clotting disorder 8. Women who are pregnant or breast-feeding

Study Design


Intervention

Drug:
Letrozole
PO daily for 14 days
Letrozole and Prometrium
PO daily for 14 days
Tamoxifen and Prometrium
PO daily for 14 days

Locations

Country Name City State
Australia St Vincent's Hospital Sydney New South Wales

Sponsors (1)

Lead Sponsor Collaborator
St Vincent's Hospital

Country where clinical trial is conducted

Australia, 

References & Publications (2)

Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Pushing estrogen receptor around in breast cancer. Endocr Relat Cancer. 2016 Dec;23(12):T227-T241. doi: 10.1530/ERC-16-0427. Epub 2016 Oct 11. — View Citation

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015 Jul 16;523(7560):313-7. doi: 10.1038/nature14583. Epub 2015 Jul 8. Erratum In: Nature. 2015 Oct 1;526(7571):144. Serandour, Aurelien A A[Corrected to Serandour, Aurelien A]. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Define a gene set as a predictive biomarker for a reduction in Ki67 Expression of gene signature will be tested in the pre- and post-intervention tissues using the Nanostring nCounter system 4 years
Other Evaluate changes in the apoptotic markers Bcl-2 and Caspase 3 in the tumors following intervention Immunohistochemistry of the pre and post intervention tissue samples 4 years
Other Evaluate changes in ER, PR, AR, FoxA1, Cyclin D1 protein and mRNA expression in the tumors following intervention Immunohistochemistry of the pre and post intervention tissue samples 4 years
Primary Geometric mean suppression of proliferation marker Ki67 The geometric mean suppression of the centrally assessed proliferation marker Ki67, after two weeks of intervention, compared with baseline After two weeks of intervention, compared with baseline
Secondary Safety and tolerability: number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Safety and tolerability of combination therapy (NCI-CTCAE v4.0) 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05528263 - Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) N/A
Completed NCT00165243 - Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer Phase 2
Recruiting NCT05559164 - Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Phase 2
Completed NCT03948568 - Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) Phase 4
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Recruiting NCT06001762 - TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer Phase 2
Active, not recruiting NCT03664687 - Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) Phase 4
Recruiting NCT04603209 - Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
Completed NCT00233077 - Patient Centered Randomized Controlled Trial N/A
Recruiting NCT02958033 - Shandong Cancer Hospital Affiliated to Shandong University Phase 3
Recruiting NCT03797248 - Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer
Recruiting NCT03788083 - Intratumoral TriMix Injections in Early Breast Cancer Patients Phase 1
Recruiting NCT05582499 - Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Phase 1/Phase 2
Recruiting NCT05871437 - Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer Phase 4
Recruiting NCT04003558 - Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)
Terminated NCT03894007 - Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Phase 2
Recruiting NCT02982148 - Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Phase 4
Active, not recruiting NCT03553797 - Accelerated Whole Breast Irradiation Hypofractionation Plus Boost VS Standard Whole Breast Irradiation Plus Boost Phase 3
Recruiting NCT06215469 - Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads) N/A
Enrolling by invitation NCT06409221 - VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study